I85PREP
⌘ K
MAC study materials
MAC study resources

MAC practice questions

One question at a time. Build your MAC understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Clinical Evaluation

What is the primary objective of a Phase I clinical trial?

  1. To compare the new treatment against the current standard of care
  2. To assess long-term post-marketing safety
  3. To determine the safe dose range and tolerability Correct answer.
  4. To confirm efficacy in a large patient population

Explanation

Phase I trials usually involve small numbers of participants and focus on safety, tolerability, and pharmacokinetics to establish a safe dosing range. Efficacy confirmation and comparisons with standard care occur in later phases.

Question 2Clinical Evaluation

What element is essential to valid informed consent?

  1. Disclosure that participation is voluntary and withdrawal is allowed Correct answer.
  2. A guarantee that the participant will receive the investigational treatment
  3. A statement that all adverse events will be compensated financially
  4. An agreement that the participant cannot discuss the trial with anyone

Explanation

Informed consent must communicate that participation is voluntary and that the person may withdraw at any time without penalty. It also includes the purpose, risks, benefits, and alternatives.

Question 3Clinical Evaluation

Why is a placebo control used in a clinical trial?

  1. To separate the drug's specific effect from nonspecific effects Correct answer.
  2. To reduce the sample size to a single participant
  3. To eliminate the need for randomization
  4. To guarantee that every participant improves

Explanation

A placebo control helps distinguish the specific effect of the treatment from placebo response, natural disease fluctuation, and observer bias. Randomization and blinding support this comparison.

Question 4Clinical Evaluation

What is a primary benefit of random assignment in a clinical trial?

  1. It balances known and unknown factors across treatment groups Correct answer.
  2. It guarantees that the treatment will be effective
  3. It allows participants to choose their preferred treatment
  4. It removes the need for a control group

Explanation

Randomization tends to balance both measured and unmeasured confounders across groups, reducing selection bias. It does not guarantee efficacy or eliminate the control group.

Question 5Clinical Evaluation

What does double-blind mean in a clinical trial?

  1. Only the statistician is aware of treatment allocation
  2. The trial has two control groups
  3. Neither participants nor investigators know the assigned treatment Correct answer.
  4. Only the participants are unaware of their treatment assignment

Explanation

Double-blind typically means both participants and investigators, and often outcome assessors, are masked to treatment allocation to prevent bias. Single-blind usually means only participants are masked.

Question 6Clinical Evaluation

What is a primary endpoint in a clinical trial?

  1. The outcome the trial is powered to measure for the main question Correct answer.
  2. The date on which the trial is stopped
  3. Any laboratory value recorded during screening
  4. The secondary safety measure collected at the end of the study

Explanation

The primary endpoint is the pre-specified outcome used to evaluate the main hypothesis and to calculate sample size and power. Secondary endpoints support or add detail but are not the basis for the primary conclusion.

Question 7Clinical Evaluation

Which description best defines an adverse event in a clinical trial?

  1. A planned hospitalization for an elective procedure
  2. Any untoward medical occurrence, whether or not treatment-related Correct answer.
  3. A protocol deviation reported by the site
  4. Any favorable health outcome observed during the trial

Explanation

An adverse event is any untoward medical occurrence temporally associated with the trial, regardless of causality. Serious adverse events meet additional severity criteria.

Question 8Clinical Evaluation

What is the main purpose of a Phase III clinical trial?

  1. To conduct post-marketing surveillance
  2. To show efficacy and safety in a larger population for approval Correct answer.
  3. To establish the maximum tolerated dose in healthy volunteers
  4. To explore pharmacokinetics in a small group

Explanation

Phase III trials are typically large, randomized, controlled studies that provide pivotal evidence of efficacy and safety for marketing approval. Phase I focuses on safety and dosing, and Phase IV occurs after approval.

Question 9Clinical Evaluation

In a randomized trial, some participants stop taking the assigned drug. Which analysis best follows the intention-to-treat principle?

  1. Participants are analyzed according to the treatment they actually received
  2. Only participants who completed the full treatment course are included
  3. All randomized participants are analyzed in their assigned groups Correct answer.
  4. Participants who switched treatments during the study are excluded

Explanation

Intention-to-treat analysis includes all randomized participants according to their assigned group, preserving the benefits of randomization and reducing attrition bias. Per-protocol and as-treated analyses condition on post-randomization behavior.

Question 10Clinical Evaluation

How does a per-protocol analysis differ from an intention-to-treat analysis?

  1. It includes all randomized participants regardless of adherence
  2. It is always the primary analysis in a pivotal trial
  3. It includes only participants who adhered to the protocol Correct answer.
  4. It requires no pre-specified analysis plan

Explanation

A per-protocol analysis includes only participants who followed the protocol, such as completing treatment and meeting eligibility, which can introduce bias by excluding non-adherent participants. Intention-to-treat includes all randomized participants.

Question 11Clinical Evaluation

In a non-inferiority trial, what does the pre-specified margin represent?

  1. The expected difference in efficacy between the two treatments
  2. The required number of participants per arm
  3. The p-value threshold for statistical significance
  4. The largest acceptable loss of efficacy versus the comparator Correct answer.

Explanation

The non-inferiority margin defines the largest loss of effect that is clinically acceptable; the confidence interval for the difference must exclude that margin. It is not the expected difference or a sample-size value.

Question 12Clinical Evaluation

Which of the following is an example of a surrogate endpoint?

  1. Quality of life score
  2. Number of hospitalizations
  3. Overall survival
  4. Change in blood pressure Correct answer.

Explanation

A surrogate endpoint is a biomarker or intermediate measure, such as blood pressure or tumor response, intended to substitute for a clinical outcome. Overall survival and hospitalizations are clinical outcomes.

Question 13Clinical Evaluation

A Type I error in hypothesis testing occurs when:

  1. The sample size is too small to detect an effect
  2. A true null hypothesis is incorrectly rejected Correct answer.
  3. A false null hypothesis is incorrectly retained
  4. The confidence interval includes the null value

Explanation

A Type I error is rejecting a true null hypothesis, which is a false-positive finding, and its probability is alpha. A Type II error is failing to reject a false null hypothesis.

Question 14Clinical Evaluation

What does statistical power represent in a clinical trial?

  1. The probability of rejecting a true null hypothesis
  2. The probability of detecting a true effect when one exists Correct answer.
  3. The probability that the treatment is safe
  4. The probability that the trial will be stopped early

Explanation

Power is 1 minus the Type II error rate and represents the chance of finding a statistically significant result if the specified effect truly exists. It depends on effect size, sample size, variability, and alpha.

Question 15Clinical Evaluation

Which interpretation of a p-value of 0.03 is most appropriate?

  1. A result this extreme would occur 3% of the time under the null Correct answer.
  2. The treatment effect is clinically meaningful
  3. There is a 3% chance the null hypothesis is true
  4. There is a 97% chance the alternative hypothesis is true

Explanation

The p-value is the probability of observing data at least as extreme as those seen, assuming the null hypothesis is true. It is not the probability that the null is true, nor does it measure clinical importance.

Question 16Clinical Evaluation

A 95% confidence interval for a risk difference is 0.5% to 4.2%. What does this indicate?

  1. The result is not statistically significant at the 0.05 level
  2. The effect is significant because the interval excludes zero Correct answer.
  3. The risk difference is exactly 2.35%
  4. There is a 95% chance the true effect lies outside this interval

Explanation

A 95% confidence interval that excludes the null value, zero for a difference, corresponds to a statistically significant result at alpha 0.05. The interval gives a range of plausible values for the effect.

Question 17Clinical Evaluation

Which design is intended to show that a new treatment is at least as good as an existing active comparator?

  1. Single-arm trial
  2. Non-inferiority trial Correct answer.
  3. Superiority trial
  4. Dose-escalation trial

Explanation

Non-inferiority trials test whether a new treatment is not unacceptably worse than an active comparator. Superiority trials aim to show that the new treatment is better.

Question 18Clinical Evaluation

What is the purpose of allocation concealment in a randomized trial?

  1. To ensure that all participants receive the active treatment
  2. To prevent investigators from anticipating upcoming assignments Correct answer.
  3. To keep participants unaware of their assigned treatment
  4. To balance the number of dropouts between groups

Explanation

Allocation concealment protects the randomization sequence until assignment is made, preventing selection bias. Blinding, by contrast, keeps participants and investigators unaware after assignment.

Question 19Clinical Evaluation

Why is a washout period used in a crossover trial?

  1. To eliminate the need for a control group
  2. To increase the sample size
  3. To allow investigators to unblind the treatment
  4. To reduce carryover effects from the prior treatment Correct answer.

Explanation

A washout period allows the effect of the first treatment to dissipate before the second period begins, reducing carryover effects. Crossover trials still require appropriate controls and blinding.

Question 20Clinical Evaluation

What is the primary role of a Data and Safety Monitoring Board (DSMB) in a clinical trial?

  1. To enroll participants in the trial
  2. To write the statistical analysis plan
  3. To conduct the primary efficacy analysis at study end
  4. To review accumulating data and advise on continuation Correct answer.

Explanation

A DSMB independently monitors trial data for safety and, when applicable, efficacy, and may recommend continuation, modification, or stopping. It does not enroll participants or perform the final primary analysis.

Question 21Clinical Evaluation

A trial's primary endpoint is a composite of cardiovascular death, myocardial infarction, and stroke. Which statement is most accurate?

  1. A significant composite result proves each component was reduced
  2. Composite endpoints eliminate the need for multiplicity control
  3. Composite endpoints require no pre-specification
  4. A significant composite does not prove each component was reduced Correct answer.

Explanation

Composite endpoints combine events to increase statistical efficiency, but the overall result can be driven by one component. Individual components should be interpreted cautiously.

Question 22Clinical Evaluation

When multiple subgroup analyses are performed without adjustment, what is the main concern?

  1. The primary endpoint becomes invalid and must be replaced
  2. The trial loses its randomization and allocation concealment
  3. The overall alpha level is reduced
  4. False-positive findings in at least one subgroup become more likely Correct answer.

Explanation

Testing many subgroups inflates the family-wise Type I error rate, increasing the likelihood of spurious findings. Pre-specification and multiplicity adjustment help control this risk.

Question 23Clinical Evaluation

Multiple imputation for missing data typically assumes that data are:

  1. Always non-informative regardless of pattern
  2. Missing not at random
  3. Missing at random given the observed data Correct answer.
  4. Missing completely at random only

Explanation

Standard multiple imputation assumes missing at random, meaning the missingness can be explained by observed variables. Missing not at random requires sensitivity analyses or different modeling approaches.

Question 24Clinical Evaluation

In a meta-analysis, an I² value of 75% most likely indicates:

  1. Substantial heterogeneity across studies Correct answer.
  2. No heterogeneity among studies
  3. A fixed-effect model is always preferred
  4. The pooled estimate is invalid

Explanation

I² estimates the proportion of variability due to heterogeneity rather than chance; 75% suggests substantial heterogeneity. This may warrant random-effects modeling and investigation of sources.

Question 25Clinical Evaluation

An interim analysis with an alpha-spending function is used mainly to:

  1. Allow unblinded investigators to decide when to stop the trial
  2. Preserve the overall Type I error rate across repeated looks Correct answer.
  3. Increase the sample size without inflating statistical power
  4. Eliminate the need for a final analysis

Explanation

Alpha-spending functions allocate a portion of the total Type I error to each interim look, preserving the overall alpha. They do not replace the final analysis or permit unblinded decision-making.

Question 26Clinical Evaluation

In a randomized trial of a topical therapy for plaque psoriasis, the dermatologist who scores lesion severity is kept unaware of each participant's treatment assignment. Which type of bias does this practice primarily reduce?

  1. Attrition bias from differential dropout
  2. Selection bias arising during randomization
  3. Bias in the publication of trial results
  4. Detection bias Correct answer.

Explanation

Blinding the person who measures the outcome prevents knowledge of treatment assignment from influencing how outcomes are assessed, which is the definition of detection (ascertainment) bias. Bias introduced at randomization is addressed by allocation concealment, not by assessor blinding.

Question 27Clinical Evaluation

A pivotal trial of a new antihypertensive enrolls only adults aged 18 to 45 with no coexisting illness, but the drug will mainly be prescribed to patients over 70 with cardiovascular disease. Which aspect of the trial is most limited?

  1. Statistical power
  2. External validity Correct answer.
  3. Inter-rater reliability
  4. Internal validity

Explanation

External validity (generalizability) is the extent to which results apply to the patients who will actually receive the treatment. Restrictive eligibility criteria can produce a well-conducted trial whose findings do not transfer to the broader clinical population.

Question 28Clinical Evaluation

Before randomization, a trial of an oral antidiabetic agent gives all eligible volunteers a single-blind placebo for four weeks. What is the main purpose of this run-in period?

  1. To remove non-adherent patients before randomization Correct answer.
  2. To increase the statistical power of the study
  3. To conceal the randomized allocation sequence from investigators
  4. To eliminate any carryover effect of previous treatments

Explanation

A placebo run-in allows adherence and tolerability to be observed before randomization, so volunteers who cannot or will not take the study medication are excluded. This reduces dilution of the treatment effect and avoidable withdrawals after randomization.

Question 29Clinical Evaluation

A trial uses randomly permuted blocks of four for allocating participants to treatment or control. What advantage does this offer over simple randomization?

  1. It removes the need for allocation concealment
  2. It keeps the arms closely balanced during enrollment Correct answer.
  3. It allows the investigator to predict the next assignment
  4. It guarantees balance on every known prognostic factor

Explanation

Block randomization forces the numbers in each arm to stay similar at the end of every block, which protects against serious imbalance if enrollment stops early or occurs in stages. It does not balance unknown or unmeasured factors and does not itself conceal the sequence.

Question 30Clinical Evaluation

A cohort study compares mortality between patients who ever received a new drug and patients who never received it. For each user, all follow-up time from cohort entry is counted as exposed, although some users did not start the drug until several months after entry. Which bias is most likely to be introduced?

  1. Attrition bias
  2. Recall bias
  3. Publication bias
  4. Immortal time bias Correct answer.

Explanation

Time before a patient could possibly have been exposed is counted as exposed follow-up; because the patient had to survive until starting the drug, that period is 'immortal' and the exposed group appears to have lower mortality. Correctly classifying person-time as unexposed until treatment initiation avoids this distortion.

Question 31Treatment Planning

Clinical treatment plans serve primarily to:

  1. summarize the assessment so the file can be closed
  2. connect assessed needs to specific services and expected outcomes Correct answer.
  3. justify the fee schedule used for billing
  4. record the counselor's preferred approach to therapy

Explanation

A treatment plan is the bridge between the assessment and the services actually delivered, so it must link each identified need to a service and an expected result. It is a working clinical document rather than a billing tool or a personal statement of counselor preference.

Question 32Treatment Planning

In a SMART goal statement, the letters stand for specific, measurable, achievable, relevant, and:

  1. theoretical
  2. time-bound Correct answer.
  3. transferable
  4. recorded

Explanation

SMART goals require a stated timeframe so progress can be evaluated at a defined point. Without a target date the goal cannot be measured for completion.

Question 33Treatment Planning

Client involvement in writing the treatment plan matters mainly because it:

  1. supports engagement and commitment to the agreed goals Correct answer.
  2. reduces the amount of documentation the counselor must complete
  3. transfers legal responsibility for treatment outcomes to the client
  4. allows the counselor to shorten the assessment process

Explanation

Plans built with the client reflect the client's own priorities, which increases buy-in and follow-through. Participation is a core principle of person-centered planning, not a shortcut for the counselor.

Question 34Treatment Planning

The problem list on a treatment plan is derived primarily from the:

  1. agency's standard weekly group schedule
  2. counselor's preferred theoretical orientation and style
  3. results of the comprehensive assessment Correct answer.
  4. client's insurance authorization and benefit limits

Explanation

Problems are identified through the comprehensive biopsychosocial assessment and then prioritized with the client. Payer limits and program schedules shape how services are delivered, not what the clinical problems are.

Question 35Treatment Planning

A strengths-based treatment plan gives explicit attention to:

  1. the client's history of legal, financial, and interpersonal problems
  2. the counselor's credentials and supervision arrangements
  3. the family's beliefs about the client's diagnosis
  4. client strengths, resources, and existing supports Correct answer.

Explanation

Strengths-based planning builds on capacities the client already has, such as skills, relationships, and recovery supports, and uses them to address identified problems. Problems are still documented, but they are not the organizing focus of the plan.

Question 36Treatment Planning

When planning care for a client from a cultural background different from the counselor's, the counselor should:

  1. ask the client to set aside cultural beliefs during treatment
  2. use the same evidence-based protocol with every client
  3. refer the client to a counselor from the same background
  4. explore cultural values and adapt goals and methods Correct answer.

Explanation

Culturally responsive planning asks about the client's values, family roles, language, and views of health, then adjusts goals and interventions so they fit the client's world. Immediate referral based on demographics alone is not required and can disrupt continuity of care.

Question 37Treatment Planning

Planning for discharge and continuing care should begin:

  1. after the client requests it
  2. at intake and continue throughout treatment Correct answer.
  3. on the client's final day of treatment
  4. when the client relapses

Explanation

Transition planning is an ongoing process that starts with the initial plan and is updated as the client progresses, so that supports are in place before services end. Waiting until discharge leaves no time to arrange housing, outpatient appointments, or recovery supports.

Question 38Treatment Planning

A treatment plan should be formally reviewed and, if needed, revised when:

  1. the client's condition or needs change significantly Correct answer.
  2. the client misses two consecutive group sessions
  3. the agency changes its electronic record vendor
  4. the counselor returns from an extended vacation

Explanation

Significant change in the client's status, needs, or level of care requires the plan to be re-evaluated so services stay matched to the client. Routine reviews also occur on a scheduled basis set by program policy or regulation.

Question 39Treatment Planning

The ASAM Criteria organize assessment information into how many dimensions used to determine appropriate level of care?

  1. four
  2. eight
  3. three
  4. six Correct answer.

Explanation

The ASAM Criteria use six dimensions, covering withdrawal and medication needs, biomedical conditions, emotional and cognitive conditions, readiness to change, relapse potential, and recovery environment. Ratings across all six are combined to match the client to a level of care.

Question 40Treatment Planning

A client reports heavy daily alcohol use with a history of severe withdrawal seizures. Under the ASAM Criteria, this information is most relevant to which dimension?

  1. Dimension 3: emotional, behavioral, and cognitive conditions
  2. Dimension 1: withdrawal and addiction medications Correct answer.
  3. Dimension 5: relapse and continued problem potential
  4. Dimension 4: readiness to change

Explanation

Dimension 1 covers intoxication, withdrawal risk, and the need for addiction medications. A history of withdrawal seizures signals medically significant withdrawal risk and typically points toward a more intensive, monitored level of care.

Question 41Treatment Planning

Which is the best-written treatment objective?

  1. Client will understand the importance of sobriety
  2. Client will improve overall functioning and mood
  3. Client will develop meaningful insight into the underlying causes of relapse
  4. Client will attend three AA meetings per week for four weeks Correct answer.

Explanation

Well-written objectives are behavioral, measurable, and time-limited, so that anyone reading the record can tell whether the objective was met. Statements about insight, understanding, or global improvement cannot be observed or counted.

Question 42Treatment Planning

A client in the precontemplation stage who attends only because of a court order is most appropriately planned for:

  1. a structured relapse prevention group with weekly drug testing
  2. engagement strategies aimed at building rapport and exploring concerns Correct answer.
  3. immediate discharge with referral to long-term residential care
  4. a contract requiring ninety days of abstinence before further sessions

Explanation

In precontemplation the client does not yet see a problem, so the plan should target engagement, alliance building, and exploration of the client's own concerns. Action-oriented interventions can be introduced later as readiness develops.

Question 43Treatment Planning

Which planning practice is most consistent with trauma-informed care?

  1. offering choices and pacing so the client feels safe and in control Correct answer.
  2. avoiding any discussion of the client's past to prevent distress
  3. requiring the client to describe traumatic events in the first session
  4. keeping the treatment plan confidential from the client to reduce distress

Explanation

Trauma-informed planning emphasizes safety, trustworthiness, choice, collaboration, and empowerment, which includes letting the client set the pace of disclosure. Neither forced disclosure nor total avoidance supports recovery.

Question 44Treatment Planning

For a client with both a substance use disorder and major depressive disorder, an integrated treatment plan should:

  1. treat the substance use first and the depression only after sustained abstinence
  2. address both conditions in one plan with coordinated goals Correct answer.
  3. defer all treatment planning until the depression fully resolves
  4. refer the client to separate agencies that do not share information

Explanation

Integrated planning treats co-occurring conditions as interacting problems addressed by one coordinated plan and one team. Sequential or parallel treatment without coordination is associated with poorer engagement and outcomes.

Question 45Treatment Planning

When a client is prescribed a medication for opioid use disorder, the treatment plan should:

  1. omit medication details to protect the client's privacy
  2. include medication adherence and coordination with the prescriber Correct answer.
  3. leave medication management entirely to the prescriber's records
  4. require that the medication be discontinued before counseling begins

Explanation

Medication for opioid use disorder is part of the client's overall treatment, so the plan should reflect adherence goals and coordination with the prescribing clinician. Excluding it produces an incomplete plan and fragmented care.

Question 46Treatment Planning

An adult client's spouse asks for information about the treatment plan. The counselor should:

  1. obtain the client's written consent before disclosing any information Correct answer.
  2. provide a general summary because the spouse lives with the client
  3. refuse to speak with the spouse under any circumstances
  4. share information only if the spouse is paying for treatment

Explanation

Substance use disorder treatment information may be disclosed to family only with the client's written consent that meets the applicable confidentiality requirements. Living together or paying for care does not create a right of access.

Question 47Treatment Planning

When several problems are identified, the plan's first priority is usually the problem that:

  1. is most likely to be covered by insurance
  2. poses the greatest immediate risk to the client's safety Correct answer.
  3. the client finds most embarrassing to discuss
  4. is easiest for the counselor to treat

Explanation

Prioritization follows clinical urgency: imminent risk to life, health, or safety comes first, followed by problems that block progress on other goals. Counselor convenience and payer coverage are not clinical prioritization criteria.

Question 48Treatment Planning

A client repeatedly declines to attend the referrals listed in the plan. The counselor should:

  1. write in the record that the client is in denial
  2. wait for the client to raise the issue at the next scheduled review
  3. document the refusal and revise the plan with the client Correct answer.
  4. close the case because the client is not motivated

Explanation

Declining services is clinically meaningful information: it is documented objectively and used to renegotiate goals and interventions with the client. Labeling the client or ending care prematurely does not address the barrier.

Question 49Treatment Planning

A client with recurrent suicidal thoughts discloses recent alcohol use. The plan should first include:

  1. a written safety plan with crisis contacts and means restriction Correct answer.
  2. a referral to vocational services
  3. a family meeting to discuss the client's childhood
  4. weekly urine screens as the sole intervention

Explanation

Suicidal ideation combined with alcohol use raises acute risk, so the initial plan must directly address safety through a documented safety plan, crisis resources, and means restriction counseling. Other needs are sequenced after imminent risk is managed.

Question 50Treatment Planning

Which best describes the counselor's role in coordinating services listed on the plan?

  1. assuming other providers will contact the counselor when needed
  2. delegating all contact with other providers to the client
  3. sending referrals and then waiting for the client to report back
  4. following up on referrals and documenting their status Correct answer.

Explanation

Service coordination is an active function: the counselor confirms whether referrals were made, whether the client was seen, and what resulted, then records that information. Passive approaches allow referrals to fail silently.